ClinConnect ClinConnect Logo
Search / Trial NCT02736110

Registry of Celution Device for the Processing of Adipose Derived Regenerative Cells (ADRCs) to Treat Osteoarthritis

Launched by CYTORI THERAPEUTICS · Apr 12, 2016

Trial Information

Current as of May 01, 2025

Withdrawn

Keywords

Osteoarthritis, Knee

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Males or females \> 18 years of age
  • Diagnosis of osteoarthritis in one or both knees with Kellgren Lawrence grade ≥ 2 at x-ray evaluation or MRI findings of degenerative changes
  • Pain with or without swelling in the affected area for \>4 months
  • Exclusion Criteria:
  • Know spine or disc disease or symptomatic nerve impingement contributing to pain in the affected limb
  • History of documented nerve damage in the affected limb
  • Pregnant or lactating status. Pregnancy as determined by a positive pregnancy test prior to procedure.

About Cytori Therapeutics

Cytori Therapeutics is a pioneering biotechnology company focused on the development and commercialization of innovative cell-based therapies aimed at addressing unmet medical needs in regenerative medicine. With a commitment to leveraging the potential of adipose-derived stem and regenerative cells, Cytori is advancing treatments for conditions such as cardiovascular disease, orthopedic injuries, and soft tissue reconstruction. The company is dedicated to rigorous clinical research and collaboration with healthcare professionals to translate scientific advancements into effective therapeutic solutions, ultimately improving patient outcomes and quality of life.

Locations

Patients applied

0 patients applied

Trial Officials

Steven Kesten

Study Chair

Cytori Therapeutics

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials